Back to top
more

Global Blood Therapeutics, Inc. (GBT)

(Real Time Quote from BATS)

$43.13 USD

43.13
10,589

-0.11 (-0.25%)

Updated Nov 24, 2020 09:52 AM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (198 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for GBT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Global Blood Therapeutics, Inc. [GBT]

Reports for Purchase

Showing records 1 - 20 ( 223 total )

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

11/20/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/06/2020

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/06/2020

Company Report

Pages: 7

Oxbryta Fundamentals Remain Intact Despite Pandemic Headwinds

Provider: Wedbush Securities Inc.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/05/2020

Company Report

Pages: 6

Oxbryta Sales Soft, but Growing - Still Found 1,000 New Patients!

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

10/27/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/07/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

09/21/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/09/2020

Company Report

Pages: 7

Expanding Access to Oxbryta® in Middle East Taps into Global SCD Opportunity

Provider: Wedbush Securities Inc.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/02/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/25/2020

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/24/2020

Company Report

Pages: 7

Oxbryta® Delivers Strong Q2-Reinforces Confidence in Long- Term Potential

Provider: Wedbush Securities Inc.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/18/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/06/2020

Company Report

Pages: 9

2Q20 Update; Oxbryta Delivers a Solid Quarter Well Ahead of What the Market Was Expecting

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/06/2020

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/06/2020

Company Report

Pages: 5

Oxbryta Sales are Much Brighter than We Thought

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

07/22/2020

Company Report

Pages: 5

Overestimated Negative COVID Impact, Raising Estimates for 2Q20

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

07/22/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

07/20/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

07/20/2020

Company Report

Pages: 33

Sickle No More, Initiation of Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Global Blood Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

07/16/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party